User profiles for "author:Sanjay de Mel"

Sanjay de Mel

Department of Haematology Oncology National University Cancer Institute Singapore
Verified email at nuhs.edu.sg
Cited by 1432

[HTML][HTML] Hematological abnormalities in COVID-19: a narrative review

A Rahman, R Niloofa, U Jayarajah… - The American journal …, 2021 - ncbi.nlm.nih.gov
ABSTRACT COVID-19 is caused by SARS-CoV-2. Although pulmonary manifestations have
been identified as the major symptoms, several hematological abnormalities have also been …

[HTML][HTML] Molecular pathogenic pathways in extranodal NK/T cell lymphoma

S de Mel, SSS Hue, AD Jeyasekharan… - Journal of hematology & …, 2019 - Springer
Extranodal NK/T cell lymphoma, nasal type (ENKTL) is an aggressive malignancy with a
dismal prognosis. Although l-asparaginase-based chemotherapy has resulted in improved …

[HTML][HTML] STAT3: a promising therapeutic target in multiple myeloma

PSY Chong, WJ Chng, S de Mel - Cancers, 2019 - mdpi.com
Multiple myeloma (MM) is an incurable plasma cell malignancy for which novel treatment
options are required. Signal Transducer and Activator of Transcription 3 (STAT3) …

[HTML][HTML] Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS

CMM Wai, S Chen, T Phyu, S Fan, SM Leong… - …, 2022 - ncbi.nlm.nih.gov
Abstract Primary Epstein-Barr virus (EBV)-positive nodal T/NK-cell lymphoma (PTCL-EBV) is
a poorly understood disease which shows features resembling extranodal NK/T-cell …

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis

PJ Teoh, O An, TH Chung, JY Chooi… - Blood, The Journal …, 2018 - ashpublications.org
DNA alterations have been extensively reported in multiple myeloma (MM); however, they
cannot yet fully explain all the biological and molecular abnormalities in MM, which remains …

An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma

J Goh, S De Mel, MM Hoppe… - Science Translational …, 2022 - science.org
Although combination therapy is the standard of care for relapsed/refractory non-Hodgkin's
lymphoma (RR-NHL), combination treatment chosen for an individual patient is empirical …

[HTML][HTML] Implications of heterogeneity in multiple myeloma

S de Mel, SH Lim, ML Tung, WJ Chng - BioMed research …, 2014 - hindawi.com
Multiple myeloma is the second most common hematologic malignancy in the world. Despite
improvement in outcome, the disease is still incurable for most patients. However, not all …

[PDF][PDF] Favipiravir in COVID-19

SL Seneviratne, V Abeysuriya, S De Mel… - International Journal …, 2020 - researchgate.net
The SARS-Cov-2 virus, emerged in December 2019 in Wuhan, China and has now spread
to all parts of the world. Many research groups are carrying out intense research on drugs …

[HTML][HTML] Temporal changes in immune blood cell parameters in COVID‐19 infection and recovery from severe infection

CYC Yip, ES Yap, S De Mel, WZY Teo… - British Journal of …, 2020 - ncbi.nlm.nih.gov
Since emerging in China in December 2019, the infection caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), coronavirus disease 2019 (COVID-19) …

A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma

XP Tian, SY Ma, KH Young, CK Ong… - Blood, The Journal …, 2021 - ashpublications.org
Current prognostic scoring systems based on clinicopathologic variables are inadequate in
predicting the survival and treatment response of extranodal natural killer/T-cell lymphoma …